Berna Biotech shareholders created the prerequisite to accept the public exchange offer of Crucell

13-Jan-2006

The extraordinary general meeting of Berna Biotech, held in Berne, created the prerequisite to accept the public Exchange offer of Crucell. It approved with about 90 percent of the represented shares the Removal of the transfer restrictions. In addition, the shareholder's meeting elected Dr. Ronald Brus, CEO of Crucell N.V., Leonhard Kruimer, CFO of Crucell N.V. and Prof. Dr. Jaap Goudsmit, CSO of Crucell N.V. to the Berna Biotech Board of Directors. They replace the retiring members of the Board of Directors, Ulrich A. Ammann, Dr. Peter Grogg, Jürg Legler and Prof. Dr. Urs B. Schaad. The decisions will only come into force if the public exchange offer of Crucell will suceed.

The Board of directors again encouraged the shareholders to accept the public offer of Crucell. The time limit for tendering the shares will expire on January 20, 2006.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances